Clinical Trial

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-03; most recent amendment 2025-10-20.
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT07167446
Lead Sponsor Fox Chase Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
Enrollment 30 participants
Start Date 2025-10-14
Primary Completion 2027-09-05 (estimated)
Study Completion 2028-09-07 (estimated)
Updated on ClinicalTrials.gov 2025-10-22